Cargando…

Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations

INTRODUCTION: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. METHODS: We reviewed...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Whitney E., Hong, Lingzhi, Mott, Frank E., Simon, George, Wu, Carol C., Rinsurongkawong, Waree, Lee, J. Jack, Lam, Vincent K., Heymach, John V., Zhang, Jianjun, Le, Xiuning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600084/
https://www.ncbi.nlm.nih.gov/pubmed/34820641
http://dx.doi.org/10.1016/j.jtocrr.2021.100237
_version_ 1784601073577623552
author Lewis, Whitney E.
Hong, Lingzhi
Mott, Frank E.
Simon, George
Wu, Carol C.
Rinsurongkawong, Waree
Lee, J. Jack
Lam, Vincent K.
Heymach, John V.
Zhang, Jianjun
Le, Xiuning
author_facet Lewis, Whitney E.
Hong, Lingzhi
Mott, Frank E.
Simon, George
Wu, Carol C.
Rinsurongkawong, Waree
Lee, J. Jack
Lam, Vincent K.
Heymach, John V.
Zhang, Jianjun
Le, Xiuning
author_sort Lewis, Whitney E.
collection PubMed
description INTRODUCTION: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. METHODS: We reviewed the database of the MD Anderson Cancer Center and identified metastatic LUSC with classic EGFR or ALK alterations. RESULTS: There were eight patients with EGFR-mutant LUSC (median age = 58 y) and six patients with EML4-ALK LUSC (median age = 50 y) who received tyrosine kinase inhibitors (TKIs) that were identified. Of the 14 patients, 11 (79%) were females and 12 (86%) were never smokers, similar to the demographics of EGFR or ALK LUAD. With TKI treatment, seven of eight cases of EGFR LUSC and four of six cases of ALK LUSC achieved partial response or stable disease, but the progression-free survival was 4.9 months and 2.9 months for EGFR-mutant and ALK-rearranged LUSC, respectively. In addition, we compared comutation profile of EGFR-mutant LUAD (The Cancer Genome Atlas, n = 46) versus LUSC (n = 19) and found that the comutation patterns are more consistent with squamous disease with a higher incidence of PIK3CA (p = 0.02) and KRAS or BRAF (p = 0.04) alterations. CONCLUSIONS: EGFR or ALK alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD.
format Online
Article
Text
id pubmed-8600084
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86000842021-11-23 Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations Lewis, Whitney E. Hong, Lingzhi Mott, Frank E. Simon, George Wu, Carol C. Rinsurongkawong, Waree Lee, J. Jack Lam, Vincent K. Heymach, John V. Zhang, Jianjun Le, Xiuning JTO Clin Res Rep Brief Report INTRODUCTION: The efficacy of targeted therapies in oncogene-driven lung adenocarcinomas (LUADs) has been well established; however, the benefit for EGFR-mutant or ALK-rearranged lung squamous cell carcinomas (LUSCs) is less known, partially owing to the rarity of the incidence. METHODS: We reviewed the database of the MD Anderson Cancer Center and identified metastatic LUSC with classic EGFR or ALK alterations. RESULTS: There were eight patients with EGFR-mutant LUSC (median age = 58 y) and six patients with EML4-ALK LUSC (median age = 50 y) who received tyrosine kinase inhibitors (TKIs) that were identified. Of the 14 patients, 11 (79%) were females and 12 (86%) were never smokers, similar to the demographics of EGFR or ALK LUAD. With TKI treatment, seven of eight cases of EGFR LUSC and four of six cases of ALK LUSC achieved partial response or stable disease, but the progression-free survival was 4.9 months and 2.9 months for EGFR-mutant and ALK-rearranged LUSC, respectively. In addition, we compared comutation profile of EGFR-mutant LUAD (The Cancer Genome Atlas, n = 46) versus LUSC (n = 19) and found that the comutation patterns are more consistent with squamous disease with a higher incidence of PIK3CA (p = 0.02) and KRAS or BRAF (p = 0.04) alterations. CONCLUSIONS: EGFR or ALK alterations occur in patients with LUSC, especially never-smoker females. TKI treatments render clinical benefit in disease control, but the duration was considerably truncated compared with those historically observed in LUAD. Elsevier 2021-10-09 /pmc/articles/PMC8600084/ /pubmed/34820641 http://dx.doi.org/10.1016/j.jtocrr.2021.100237 Text en © 2020 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Brief Report
Lewis, Whitney E.
Hong, Lingzhi
Mott, Frank E.
Simon, George
Wu, Carol C.
Rinsurongkawong, Waree
Lee, J. Jack
Lam, Vincent K.
Heymach, John V.
Zhang, Jianjun
Le, Xiuning
Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_full Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_fullStr Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_full_unstemmed Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_short Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations
title_sort efficacy of targeted inhibitors in metastatic lung squamous cell carcinoma with egfr or alk alterations
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8600084/
https://www.ncbi.nlm.nih.gov/pubmed/34820641
http://dx.doi.org/10.1016/j.jtocrr.2021.100237
work_keys_str_mv AT lewiswhitneye efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT honglingzhi efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT mottfranke efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT simongeorge efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT wucarolc efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT rinsurongkawongwaree efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT leejjack efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT lamvincentk efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT heymachjohnv efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT zhangjianjun efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations
AT lexiuning efficacyoftargetedinhibitorsinmetastaticlungsquamouscellcarcinomawithegfroralkalterations